On Wednesday, Labcorp Holdings got a positive adjustment to its Relative Strength (RS) Rating, from 67 to 73.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's unique RS Rating tracks market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history shows that the best stocks tend to have an RS Rating of above 80 in the early stages of their moves. See if Labcorp Holdings can continue to show renewed price strength and hit that benchmark.
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to establish and enter a buying range in heavy volume.
The company posted 4% EPS growth in its most recent report. Revenue gains came in at 5%. Keep an eye out for the company's next round of numbers on or around Jul. 24.
The company holds the No. 11 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Progyny and GeneDx Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
